200 related articles for article (PubMed ID: 19901553)
1. Epigenetic alterations in a murine model for chronic lymphocytic leukemia.
Chen SS; Sherman MH; Hertlein E; Johnson AJ; Teitell MA; Byrd JC; Plass C
Cell Cycle; 2009 Nov; 8(22):3663-7. PubMed ID: 19901553
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.
Chen SS; Raval A; Johnson AJ; Hertlein E; Liu TH; Jin VX; Sherman MH; Liu SJ; Dawson DW; Williams KE; Lanasa M; Liyanarachchi S; Lin TS; Marcucci G; Pekarsky Y; Davuluri R; Croce CM; Guttridge DC; Teitell MA; Byrd JC; Plass C
Proc Natl Acad Sci U S A; 2009 Aug; 106(32):13433-8. PubMed ID: 19666576
[TBL] [Abstract][Full Text] [Related]
3. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
[TBL] [Abstract][Full Text] [Related]
4. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
5. Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL.
Pekarsky Y; Palamarchuk A; Maximov V; Efanov A; Nazaryan N; Santanam U; Rassenti L; Kipps T; Croce CM
Proc Natl Acad Sci U S A; 2008 Dec; 105(50):19643-8. PubMed ID: 19064921
[TBL] [Abstract][Full Text] [Related]
6. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression.
Bichi R; Shinton SA; Martin ES; Koval A; Calin GA; Cesari R; Russo G; Hardy RR; Croce CM
Proc Natl Acad Sci U S A; 2002 May; 99(10):6955-60. PubMed ID: 12011454
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells.
Ougolkov AV; Bone ND; Fernandez-Zapico ME; Kay NE; Billadeau DD
Blood; 2007 Jul; 110(2):735-42. PubMed ID: 17463171
[TBL] [Abstract][Full Text] [Related]
8. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
[TBL] [Abstract][Full Text] [Related]
10. Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.
Lascano V; Guadagnoli M; Schot JG; Luijks DM; Guikema JE; Cameron K; Hahne M; Pals S; Slinger E; Kipps TJ; van Oers MH; Eldering E; Medema JP; Kater AP
Blood; 2013 Dec; 122(24):3960-3. PubMed ID: 24100449
[TBL] [Abstract][Full Text] [Related]
11. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
[TBL] [Abstract][Full Text] [Related]
12. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
13. Expression analysis of the epigenetic methyltransferases and methyl-CpG binding protein families in the normal B-cell and B-cell chronic lymphocytic leukemia (CLL).
Kn H; Bassal S; Tikellis C; El-Osta A
Cancer Biol Ther; 2004 Oct; 3(10):989-94. PubMed ID: 15467427
[TBL] [Abstract][Full Text] [Related]
14. Is miR-29 an oncogene or tumor suppressor in CLL?
Pekarsky Y; Croce CM
Oncotarget; 2010 Jul; 1(3):224-7. PubMed ID: 20936047
[TBL] [Abstract][Full Text] [Related]
15. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.
Chen SS; Claus R; Lucas DM; Yu L; Qian J; Ruppert AS; West DA; Williams KE; Johnson AJ; Sablitzky F; Plass C; Byrd JC
Blood; 2011 Jan; 117(3):862-71. PubMed ID: 21098398
[TBL] [Abstract][Full Text] [Related]
16. The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia.
Röder B; Fahnenstiel H; Schäfer S; Budeus B; Dampmann M; Eichhorn M; Angermüller S; Brost C; Winkler TH; Seifert M; Nitschke L
EMBO Rep; 2023 Aug; 24(8):e56420. PubMed ID: 37424400
[TBL] [Abstract][Full Text] [Related]
17. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
[TBL] [Abstract][Full Text] [Related]
18. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065
[TBL] [Abstract][Full Text] [Related]
19. Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL.
Wierzbinska JA; Toth R; Ishaque N; Rippe K; Mallm JP; Klett LC; Mertens D; Zenz T; Hielscher T; Seifert M; Küppers R; Assenov Y; Lutsik P; Stilgenbauer S; Roessner PM; Seiffert M; Byrd J; Oakes CC; Plass C; Lipka DB
Genome Med; 2020 Mar; 12(1):29. PubMed ID: 32188505
[TBL] [Abstract][Full Text] [Related]
20. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics.
Speedy HE; Beekman R; Chapaprieta V; Orlando G; Law PJ; Martín-García D; Gutiérrez-Abril J; Catovsky D; Beà S; Clot G; Puiggròs M; Torrents D; Puente XS; Allan JM; López-Otín C; Campo E; Houlston RS; Martín-Subero JI
Nat Commun; 2019 Aug; 10(1):3615. PubMed ID: 31399598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
